183 related articles for article (PubMed ID: 3015011)
1. Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.
Gutmann L; Kitzis MD; Yamabe S; Acar JF
Antimicrob Agents Chemother; 1986 May; 29(5):955-7. PubMed ID: 3015011
[TBL] [Abstract][Full Text] [Related]
2. Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors.
Moosdeen F; Keeble J; Williams JD
Rev Infect Dis; 1986; 8 Suppl 5():S562-8. PubMed ID: 3026004
[TBL] [Abstract][Full Text] [Related]
3. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S
Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
[TBL] [Abstract][Full Text] [Related]
4. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.
Aronoff SC; Jacobs MR; Johenning S; Yamabe S
Antimicrob Agents Chemother; 1984 Oct; 26(4):580-2. PubMed ID: 6097169
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.
Higashitani F; Hyodo A; Ishida N; Inoue M; Mitsuhashi S
J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of YTR 830.
Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S
J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029
[TBL] [Abstract][Full Text] [Related]
7. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
Akova M; Yang Y; Livermore DM
J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
[TBL] [Abstract][Full Text] [Related]
8. Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.
Appelbaum PC; Jacobs MR; Spangler SK; Yamabe S
Antimicrob Agents Chemother; 1986 Nov; 30(5):789-91. PubMed ID: 3026241
[TBL] [Abstract][Full Text] [Related]
9. In-vitro evaluation of ampicillin/brobactam and comparison with other beta-lactam antibiotics.
Melchior NH; Keiding J
J Antimicrob Chemother; 1991 Jan; 27(1):29-40. PubMed ID: 1646779
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
Gatermann S; Marre R
Infection; 1991; 19(2):106-9. PubMed ID: 1646771
[TBL] [Abstract][Full Text] [Related]
11. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria.
Kitzis MD; Ferré B; Coutrot A; Acar JF; Gutmann L
Eur J Clin Microbiol Infect Dis; 1989 Sep; 8(9):783-8. PubMed ID: 2556277
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo efficacy of YTR-830H and piperacillin combinations versus beta-lactamase-producing bacteria.
Kuck NA; Petersen PJ; Weiss WJ; Testa RT
J Chemother; 1989 Jun; 1(3):155-61. PubMed ID: 2552030
[TBL] [Abstract][Full Text] [Related]
14. [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro].
Blahová J; Hupková M; Krcméry V
Cas Lek Cesk; 1995 Sep; 134(17):558-61. PubMed ID: 7553760
[TBL] [Abstract][Full Text] [Related]
15. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.
Payne DJ; Cramp R; Winstanley DJ; Knowles DJ
Antimicrob Agents Chemother; 1994 Apr; 38(4):767-72. PubMed ID: 8031044
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).
Eliopoulos GM; Klimm K; Ferraro MJ; Jacoby GA; Moellering RC
Diagn Microbiol Infect Dis; 1989; 12(6):481-8. PubMed ID: 2560420
[TBL] [Abstract][Full Text] [Related]
17. Interaction of clavulanic acid, sulbactam and cephamycin antibiotics with beta-lactamases.
Grace ME; Fu KP; Gregory FJ; Hung PP
Drugs Exp Clin Res; 1987; 13(3):145-8. PubMed ID: 3040368
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam.
Moosdeen F; Williams JD; Yamabe S
Antimicrob Agents Chemother; 1988 Jun; 32(6):925-7. PubMed ID: 2843088
[TBL] [Abstract][Full Text] [Related]
19. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
Piddock LJ; Jin YF; Turner HL
J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
[TBL] [Abstract][Full Text] [Related]
20. Effects of tazobactam on the frequency of the emergence of resistant strains from Enterobacter cloacae, Citrobacter freundii, and Proteus vulgaris (beta-lactamase derepressed mutants).
Higashitani F; Nishida K; Hyodo A; Inoue M
J Antibiot (Tokyo); 1995 Sep; 48(9):1027-33. PubMed ID: 7592048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
